Drug Type Bispecific antibody |
Synonyms SY 2030, SY2030 |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), F11 inhibitors(Coagulation factor XI inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Venous Thromboembolism | Preclinical | CN | 28 Sep 2024 |